The combination of sunitinib and CAIX-specific CAR T cells administered in mice bearing lung metastases of human RCC showed synergistic efficacy, enhanced proliferative capacity, and migration into the tumor compared to anti-CAIX CAR T cells or sunitinib treatment alone [108]. This evidence concerns the gene CA9 and neoplasm.